Immunomonitoring of Breast Cancer Patients During Systemic Treatment

Study Overview
=================
Brief Summary
-----------------
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.

Detailed Description
-----------------
The main objective of this study is to describe, depending on the type of systemic treatment received, the blood immune response before treatment and its evolution under treatment.

Official Title
-----------------
Immunomonitoring of Breast Cancer Patients During Systemic Treatment

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Woman aged between 18 and 85. Patient with histologically proven infiltrating breast cancer. Triple negative breast cancer or RH + / HER2- (OR and RP <10% and HER2 negative (0 or 1+ in IHC or 2+ in IHC and FISH negative) Patient receiving treatment corresponding to one of these cohorts: In a metastatic situation with establishment of treatment with Paclitaxel regardless of the treatment line In a metastatic situation with establishment of treatment with Epirubicin - cyclophosphamide (EC) regardless of the treatment line In a metastatic situation with establishment of treatment with Eribulin regardless of the line of treatment In a 1st line metastatic situation with initiation of treatment with Palbociclib or Abemaciclib, or Ribociclib in combination with hormone therapy (aromatase inhibitor) Patient who signed the informed consent for the study. Patient fit and able to adhere to protocol for the duration of the study, including visits, scheduled specimens and follow-up. Patient affiliated to the social security system. Exclusion Criteria: Patient unable to understand, read and / or sign informed consent. Presence of cerebral or meningeal metastasis Current or previous use of an immunosuppressive drug in the 14 days preceding inclusion (except intranasal corticosteroids, systemic corticosteroids at physiological doses not exceeding 10 mg per day of prednisone or its equivalent, corticosteroids for antiemetic purposes, corticosteroids used as premedication for hypersensitivity reactions (injected CT scan, taxanes, etc.) Patient participating in another research that may modify the systemic treatment administered in the framework of the cohort in which she will be included. Pregnant or breastfeeding woman. HIV and / or HBV and / or HCV serology positive. Life expectancy estimated at less than 3 months. Patient's refusal. Person benefiting from a protection system for adults (including tutorship and curatorship). Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>4 différents cohorts: Paclitaxel cohort (N=30) Epirubicine - cyclophosphamide cohort (N=30) Eribuline cohort (N=30) Palbociclib (N=20) ou Abemaciclib (N=20) ou Ribociclib cohort (N=21) Study diagram : Inclusion and screening visite Visit 1: J1C1 Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort Visit 3 :J21C1 Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort During these visits, we collect, before the start of treatment administration ; Vital signs, Concomitant treatments, Blood sample: 1 heparinized tube (4 mL) for collection of plasma and storage 1 heparinized tube (4 mL) for immunophenotyping, 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation. | Other: blood sample<br>* •Blood sample: 1 heparinized tube (4 mL) for collection of plasma and storage 1 heparinized tube (4 mL) for immunophenotyping, 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood immune response blood immune response blood immune response | realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
immune response, blood samples